Cystic Fibrosis Foundation Participates in HHS Roundtable on Drug Pricing

Yesterday, the Cystic Fibrosis Foundation met with HHS Secretary Tom Price and seven other patient advocacy groups to discuss drug pricing and the needs of the CF community. President Trump has identified drug pricing as a top priority, and this meeting was the start of a listening tour by the Secretary.

| 2 min read

As an advocate for the CF community, the Foundation accepted the opportunity to meet with the administration and to reinforce that people with CF need access to high-quality, specialized care -- a core component of the Foundation's mission.

“We are concerned about the effect of cost on patients,” said Mary Dwight, senior vice president of policy and advocacy. “We don't have the solution but we are working to ensure that the needs of people with cystic fibrosis are represented in the ongoing discussions to develop an approach that will allow continued access to innovative, life-saving treatments.”

At the meeting, the Foundation shared how we view drug pricing through the lens of our policy principles:

  • Affordability: Treatments are priced at a point that does not prohibit access for patients;
  • Adequacy: Pricing and coverage decisions should be rooted in clinical evidence to support patients' access to high-quality therapies and care that reflect the latest research, clinical guidelines, and best practices;
  • Availability: Patients should be able to access therapies and care regardless of an individual's income, employment, health status, or geographic location; and
  • Transparency: Decisions about how prices are set and coverage decisions are made must be transparent.

The event was attended by Dwight and Sara Singleton, senior director of research, drug discovery and development policy at the Foundation. Other groups in attendance included the Alzheimer's Association, the American Diabetes Association, Friends of Cancer Research, JDRF, the Multiple Sclerosis Coalition, the National Alliance on Mental Illness, and the National Health Council.

Share this article
Recent news
CF Foundation Provides Up to $3.9M to TB Alliance to Further Develop an NTM Drug
News | 2 min read
CF Foundation Advocates to Protect Needs of People With CF in Post-Pandemic Medicaid Redeterminations
News | 5 min read
FDA Approves Kalydeco for Infants as Young as 1 Month
News | 4 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.